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Abstract  
Introduction: Breast cancer is the most common cancer among women worldwide. Sulfotransferase 
plays an important role in the formation of estrogen which is usually conferred as a risk factor for 
breast cancer. The SULT1A1*2 polymorphism is likely to play an important role in the susceptibility 
to breast cancer. This polymorphism (G638A) in the sulfotransferase 1A1 (SULT1A1) gene may 
causes Arg213His amino acid change and consequently results in significantly reduced enzyme 
activity and thermostability. 
Materials and Methods: In this case-control study, we investigated the role of SULT1A1 G638A 
polymorphism in breast cancer patients. We genotyped 144 patients with breast cancer and 116 
healthy control subjects, using a Polymerase chain reaction –Restriction Fragment length 
polymorphism (PCR-RFLP) method. 
Results: The frequencies of SULT1A1 G638G, G638A and A638A were 83.5%, 17.8%, and 1.4% in 
the breast cancer group and 89.5%, 4.0% and 0.0% in the control group. The results of our study 
indicate that the SULT1A1 G638A genotype showed 4.6 folds increased risk of breast cancer (p = 
0.002).  
Conclusion: In conclusion, our results suggest that, SULT1A1 G638A variant is significantly 
associated with risk of breast cancer in south Indian women. 
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Introduction 
The risk of hormone dependent cancer is 
directly or indirectly related to reproductive 
hormones in particular estrogen. Estrogen 
stimulation plays an important role in human 
breast cancer cell growth and development. It 
was reported that estrogen could affect breast 
cancer risk through stimulating cellular 
proliferation and promoting tumor progression 
[1]. To date, 13 human cytosolic SULT 
isoforms have been identified and grouped as 
four major families: SULT1, SULT2, SULT4 
and SULT6 [2] Sulphotransferase (SULT1A1) 
gene locates in chromosome 16p11.2 - p12.1. 
SULT1A1 gene belongs to the superfamily and 
catalyzes sulfate conjugation and plays a 
significant role in the phase II metabolism of a 
large number of endogenous and exogenous 
compounds [3]. It is evident from previous 
studies that SULT1A1 gene also acts as an 
isoform for the sulfation of estrogen and 
catecholestrogen in breast cancer forming 
hydrophilic sulphates of estrogen which are 
excreted in urine [4]. 
Cancer susceptibility has been proposed to be 
influenced by functional polymorphism in 
enzyme metabolizing carcinogenic substrates. 
A common polymorphism in exon 7 of the 
SULT1A1 gene results in the substitution of a 
histidine for an arginine at position 213 of the 
translated protein, which in turn produces an 
enzyme with much lower catalytic activity and 
decreased thermal stability [5]. The variant 
allele SULT1A1*2 with reduced 
sulfotransferase activity might enhance the risk 
of bone marrow cancer [6]. Two previous 
studies [7, 8] reported the SULT1A1*2 
polymorphism associated with breast cancer. 
Recently Wang et al. meta-analyzed the 
relationships between SULT1A1 and breast 
cancer risk [9] and concluded that there was no 
significant relationship between SULT1A1 
R213 H polymorphism and the risk of breast 
cancer. Previous studies have shown 
inconsistent results for the association between 
the SULT1A1 G638A polymorphism and 
several malignancies including bladder cancer, 
ovarian cancer and prostate cancer [10]. 
Therefore, we conducted case-control study to 
explore the role of SULT1A1 G638A 
polymorphism in the development of breast 
cancer in south Indian population. 
Materials & Methods 
Study population  
Breast carcinoma patients were assessed on the 
basis of clinical and pathological examinations. 
This Study is a Hospital-based case-control 
study conducted in South Indian population. 
All incidents of breast cancer cases were newly 
diagnosed during the study period Mahavir 
hospital Ethical committee approved the study 
for the benefit of humans in general. The 
procedures followed were in accordance with 
the ethical standards of responsible committee 
of the Institutes/Hospitals, to participate in a 
face-to-face interview using a structured 
questionnaire. We obtained informed consent 
from the study participants. 
Selection Criteria 
Senior pathologists confirmed all diagnoses. 
We interviewed and collected the data about 
the patient’s demographic factors; we collected 
the information on age, smoking, chewing, 
usual alcohol intake, and previous cancer 
diagnoses. Participants were also asked about 
their family history of cancer, and the clinical 
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information for these cases was obtained from 
medical records like tumor size, stage, and 
whether they were receiving chemotherapy, 
and radiotherapy. Patients were recruited 
following certain inclusion and exclusion 
criteria, which were determined before the 
beginning of the study. 
Inclusion & Exclusion Criteria 
All new cases of clinically confirmed breast 
cancer would be taken for study. Patients of 
confirmed breast cancer who give their consent 
were included. All patients who refused to give 
consent were excluded.  
DNA Isolation 
DNA was isolated from the tissue samples from 
breast cancer patients and blood samples from 
healthy volunteers by a rapid non-enzymatic 
method by salting out cellular proteins with 
saturated solution and precipitation by 
dehydration [11]. The red blood cells were 
lysed completely using RBC lyses solution. 
The lysate were then treated with cell lysis 
solution in order to lyse the cell components. 
The protein content was removed by protein 
precipitation solution. The precipitated DNA 
was suspended in 70% ethanol in order to 
remove the salts. The DNA was then dissolved 
in TE buffer and stored at 4°C Cell lysis, 
protein precipitation. DNA precipitation and 
DNA hydration were carried out in the 
experiment. 
Genotyping of SULT1A1*2 Polymorphisms 
Polymerase chain reaction (PCR) was 
performed, with specific primers synthesized 
from bioserve Biotechnologies Ltd. 
(Hyderabad, India): 
5'-TCCAGAATCTGTTCCAGAGCGTGC-3'(f
orward) and 5’- 
CTTGGGGAGAACCATCCTCA -3' (reverse). 
A three-step PCR was standardized using an 
takara thermocycler and carried out with 
initial denaturation at 94°C for 5 min, 
followed by 35 cycles of denaturation at 94°C 
for 30 s, annealing at 58°C for 30 s, and 
extension at 72°C for 45 s. A final extension at 
72°C for 5 min was carried out. Amplification 
products corresponding to 200bp were 
visualized after electrophoresis in an 
ethidium-bromide-stained 2% agarose gel. 
RFLP was conducted with PCR amplified 
product using Hha1 (Fermentas)restriction 
enzyme for 370C overnight PCR products 
subjected to enzyme digestion were visualized 
on 3% agarose gel stained with ethidium 
bromide (Fig-3). 
Statistical Analysis 
All statistical analysis odds ratio(OR), 95% 
confidential intervals (CI) and Probability(P) 
values were done using the MedCalc for 
Windows, version 7.4.1.0 (MedCalc Software, 
Mariakerke, Belgium). Values less than 
P<0.05 were regarded as statistically 
significant. 
Results 
The present study was carried out in 144 
sporadic Breast Cancer patients and 116 
healthy age matched women volunteers. The 
study was approved by ethical committee and 
informed consent was taken. Age range for BC 
patients was 28 – 78 years. The mean age at 
which Breast Cancer was identified 49.87 
years. Breast Cancer patients were divided 
into 3 groups according to age at diagnosis, 
these are 20-39, 40-59 and 60 years above. 
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Incidence of breast cancer was high in the age 
groups 40-59(64%) years when compared to 
other age groups, and the incidence was very 
low in the age group 21-30 followed by 71-80 
years. It was observed that the majority of 
sporadic that breast cancer cases were high in 
postmenopausal group when compared to 
premenopausal group. In the present study all 
cases are invasive ductal carcinomas The 
categorization according to hormone receptor 
status which was determined by IHC was as 
follows ER-/PR-, ER+/ PR+, ER+/PR- and 
ER-/PR+. The percentage of ER+PR+ 
(36.36%) and ER-PR- (49.53%) breast tumors 
were high when compared to other tumor 
subtypes like ER+/PR- (9.34%) , ER-/PR+ 
(9.34%), ER+/PR-, ER-/PR+ tumor showed 
equal distribution. In the present study Grade 
II showed the highest frequency followed by 
(61.25%) when compared to Grade III 
(21.25 %), other types of tumor grade like 
Grade I (17.5%) showed very low frequency 
when compared to Grade II and Grade III 
types (Table 1). 
 
Table 1 Clinical and pathological features 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sulfotransferase 1A1 (SULT1A1) G638A 
Genotyping Analysis 
SULT1A1 G638A Gene polymorphisms were 
analyzed in DNA obtained from Tissue 
samples of 144 Breast Cancer patients and 
compared to 116 healthy age matched women 
volunteers blood samples. SULT1A1 G638A 
Polymorphism was analyzed by PCR –RFLP 
and the PCR product (200bp) was digested 
with Hha1 restriction enzyme. The DNA 
fragments were then separated using 2 % 
agarose gel and detected by ethidium bromide 
staining. The absence of restriction site, which 
gave a 200bp fragment, indicates A allele, 
heterozygous GA genotype shows 200, 160 
and 40bp (Figure 1 & 2) bands and wild type 
GG genotype shows 160 and 40 bp bands.  
 
 
 
 
 
Figure 1 SULT1A1 PCR products after restriction 
digestion with HhaI on 2% agarose gel. 
Lane 1 = 100bp DNA Ladder, Lane 2&3 = GA 
genotype, Lane 4 = AA genotype and Lane 5 =GG 
genotype 
 
G638A 
 
              
Figure 2 G-A alteration at nucleotide position 638 
in Exon 4 Junction  
 
Total cases 144(100%) 
 
Age Range  
20-39 
40-59 
   
 
46(32%) 
92(64%) 
 
Menopausal 
Status 
Postmenopausal 
 
 
91(63%) 
53(37%) 
Hormonal Status 
ER+/PR+ 
ER-/PR- 
 
 
 
51(36%) 
69(48%) 
 
 
Nuclear Grade 
Grade-I 
Grade-II 
 
 
25(17%) 
88(62%) 
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Frequencies of  GG, GC, and CC 
genotypes were 83.5%(n=117), 17.8%(n=25), 
1.4%(n=2) in the breast cancer cases and 
89.5%(n-111), 4%(n=5), 0.00%(n=0) in the 
controls respectively. Table 2 shows results 
for the SULT1A1 G638A Polymorphism, GA, 
and AA genotypes showed higher frequency in 
breast cancer patients than controls. From 
SULT1A1 Genotyping Analysis, it was 
observed that there was no significant 
difference in the distribution of GG genotype 
between cases (83.5%) and controls (89.5%).  
AA genotype was observed only in 1.4% of 
breast cancer cases and it was absent in the 
control group, While the distribution of GA 
genotype was higher in breast cancer cases 
(17.8%) when compared to controls (4.0%). 
Odds ratios (OR: 4.66, 95% CI: 1.72-12.60) 
and p values (0.002)   showed an association 
of IM genotype with Breast Cancer. In this 
study SULT1A1 G allele frequency was 
0.899%, A allele frequency was 0.11%in the 
breast cancer patients and G allele frequency 
was 0.978%, A allele frequency was 0.021% in 
the controls suggesting that individual alleles 
were associated (p-value 0.001) with breast 
cancer (Table 12). In SULT1A1 (G638A) 
genotype, a total of 288 alleles were reported 
of which, 29 were mutant and 259, wild type 
(Table 2) 
 
Table 2 Distribution of SULT1A1 gene G638A polymorphism in Breast Cancer patients and controls 
 
 
 
 
 
 
 
 
 
 
 
 
Correlation analysis of SULT1A1 G638A 
polymorphism and breast cancer clinical 
characteristics 
From this analysis it was observed that, GG 
genotype distribution was lower in both pre 
and post menopausal breast cancer patients 
when compared to controls.  The difference 
in the distribution of GA genotype between 
breast patients and controls was significant; 
these were elevated in premenopausal breast 
cancer patients. Whereas only 2% of the post 
menopausal breast cancer patients showed PM 
(Poor Metabolizer) genotype, none of the pre 
menopausal breast cancer patients and 
controls showed this genotype. Genotyping 
analysis of SULT1A1 with respect to ER/PR 
status showed that distribution of GA and AA 
genotypes of SULT1A1 between ER/PR 
positive and ER/PR negative breast cancer 
patients. High frequency of GA genotype was 
found to be ER-ve patients. From the 
correlation analysis of SULT1A1 genotyping, 
it was observed that, the AA genotype was not 
seen in both Grade 1 and Grade II. Slight 
increase of GA genotype from Grade I to 
Grade III was observed, however the 
difference was not significant in all the 3 
grades of GA & GG genotypes (Table 3).                                          
Genotype Cases 
(n=144) 
Controls 
(n=116) 
OR 95%CI X2 P-value 
G638G 117(83.5%) 111(89.5%) 0.19 0.07 - 0.52 11.11 0.001 
G638A 25(17.8%) 5(4.0%) 4.66 1.72 -12.60 9.48 0.002 
A638A 2(1.4%) 0(0.00%) 4.08 0.19 – 85.9 0.31 0.365 
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Table 3 Correlation analyses of SULT1A1 G638A polymorphism and breast cancer clinical characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
SULT1A1 is the primary sulfotransferase 
isoform responsible for the sulfation of 4-OH 
TAM [12](Falany CN et al., 1997). Sulfation 
of compounds such as estradiol is generally 
considered to result in their inactivation, in 
that sulfated estrogens are poor ligands for the 
estrogen receptor. The most common 
polymorphism in the SULT1A1 gene being  a 
G •  A transition at nucleotide 638, which 
results in an arginine to histidine substitution 
at the conserved amino acid 213, and has been 
associated with a decreased sulfotransferase 
activity. From the analysis of SULT1A1 
genotypes among breast cancer patients, we 
found that the distribution of heterozygous 
mutant genotype between breast cancer 
patients and controls was significant; this 
appears to be associated with breast cancer. 
While the distribution of homozygous mutant 
genotype was more in breast cancer patients 
than in controls, however the result was not 
statistically significant.  An A allele showed 
significant association with breast cancer. 
Correlation analysis of SULT1A1 genotypes 
with menopausal status, observed a significant 
association of GA genotypes with 
premenopausal women breast cancer patients, 
suggesting that this may be associated with 
early onset of the disease. This finding is 
consistent with earlier report which shows that 
His SULT1A1 allele increased the risk in 
premenopausal patients. Breast cancer patients 
with ER/PR negative tumors showed an 
association with heterozygous SULT1A1 
genotype. Significant association of this 
polymorphism with disease progression was 
observed hence there was difference in the 
distribution of SULT1A1 genotypes between 
breast cancer patients with different grades. 
Breast cancer patients with SULT1A1 
genotype showed a significant association 
with response. Moreover there was a positive 
association Arg/His genotypes with 
premenopausal women and with ER/PR 
negative cases which puts the cases at 
increased risk. 
Clinical Data GG(n=117) GA(n=25) AA(n=2) 
Menopausal Status 
Post Menopausal 
Pre Menopausal 
 
85% (99) 
70%(82) 
 
12% (14) 
30%(35) 
 
3% (4) 
0%(0) 
Hormonal Status 
ER+/PR+ 
ER-/PR- 
 
76%(89) 
60%(70) 
 
19%(22) 
38%(45) 
 
5%(6) 
2%(2) 
Nuclear Grade 
Grade-I 
Grade-II 
Grade-III 
 
75%(87) 
70%(82) 
69%(81) 
 
25%(30) 
26%(32) 
31%(36) 
 
0%(0) 
4%(3) 
0%(0) 
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According to previous studies, his allele of 
SULT1A1 was found to involve in the 
inactivation of estrogen, the hormone is 
believed to play important role in etiology of 
breast cancer. Wei Zheng in a case – control 
study reported that postmenopausal women 
who were with His/His allele at codon 213 of 
SULT1A1 gene may be at an increased risk of 
breast cancer, and patients with Arg/His were 
also found to be at higher risk with breast 
cancer [7]. Tang D et al. found no risk in 
Arg/His breast cancer patients [8]. Ding-Fen 
Han et al. suggest that the SULT1A1 His allele 
was positively associated with the risk of 
breast cancer in Chinese women [13]. It 
appears that there is an interaction between 
SULT1A1 polymorphism and related exposure 
factors. Monique Saintot et al. reported that 
His SULT1A1 allele increased the risk only in 
premenopausal patients [14]. One in Indian 
study reported that the genetic polymorphisms 
of the SULT1A1 gene is associated with an 
increased risk of breast cancer among 
postmenopausal Kerala women [15]. It was 
found that this allele lowers sulfation of the 
tobacco carcinogens among women with His 
SULT1A1 could increase exposure to 
genotoxic compounds; SULT1A1 induces the 
individual susceptibility to breast cancer 
among current smokers. Nowell and 
colleagues showed that the high-activity allele 
SULT1A1*1 contributed significantly to 
tamoxifen response [16]. They suggested that 
sulfation may affect bioavailability of 
4-OH-tamoxifen by reduced clearance of the 
sulfated metabolite. This may provide a 
genotype-dependent reservoir of inactivated 
metabolite, which can be desulfated by steroid 
sulfatase expressed in breast tumours and can 
be recovered to the active 4-OH-tamoxifen, 
leading to a prolonged anti-oestrogen effect 
[17]. The majority of studies suggest that 
genetic polymorphisms in xenobiotic 
metabolizing enzymes may play an important 
role in the susceptibility of individuals to 
cancer [18]. In our previous study, we found 
that the CYP2D6 genotype may play an 
important role as a risk factor for breast 
cancer development in the south Indian 
population [11]. In conclusion the SULT1A1 
G638A was significantly associated with an 
increased risk for early onset of the breast 
cancer. However the detection of SULT1A1 
polymorphisms has important clinical 
implications for diagnosis, and therapy.  
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